Followers | 40 |
Posts | 1195 |
Boards Moderated | 0 |
Alias Born | 06/22/2015 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, May 21, 2016 1:42:05 PM
Such crap, oh well, exits Monday...or not ;).
Carbylan Therapeutics, Inc.
Johnson & Weaver, LLP is investigating potential violations of the federal securities laws by Carbylan Therapeutics, Inc. (NASDAQ: CBYL) and certain of its officers in connection with the Company's initial public offering (IPO). Specifically, Johnson & Weaver's investigation seeks to determine whether certain statements regarding the Company's business metrics and financial prospects were not as strong as represented in the Registration Statement.
On May 12, 2016 the Company reported net losses of approximately $6.6 million and $5.2 million in the three months ended March 31, 2016 and 2015, respectively.
If you have information that could assist in this investigation, or if you are a Carbylan shareholder who suffered a loss on that investment and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker (jimb@johnsonandweaver.com) by email or by phone at 619-814-4471. If emailing, please include a phone number where you can be reached.
The Phenomenon only provides his/her opinion. Do your own DD, or don't, but my thoughts are my opinion only and not to be taken as advice.
Recent KALV News
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 07/02/2024 10:30:00 AM
- KalVista Initiates KONFIDENT-KID Trial for On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11 • Business Wire • 06/27/2024 10:30:00 AM
- KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema • Business Wire • 06/18/2024 10:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/10/2024 10:42:49 PM
- KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024 • Business Wire • 06/06/2024 10:30:00 AM
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 06/04/2024 10:30:00 AM
- KalVista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024 • Business Wire • 06/03/2024 10:30:00 AM
- KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema • Business Wire • 05/31/2024 08:09:00 PM
- KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema • Business Wire • 05/31/2024 04:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 08:10:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 08:08:43 PM
- KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024 • Business Wire • 05/24/2024 10:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 09:59:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 09:58:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 09:57:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 09:55:36 PM
- KalVista Pharmaceuticals to Present at Upcoming Investor Conferences • Business Wire • 05/21/2024 10:30:00 AM
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 05/02/2024 10:30:00 AM
- KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year • Business Wire • 05/01/2024 10:30:00 AM
- KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors • Business Wire • 04/22/2024 10:30:00 AM
- KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference • Business Wire • 04/03/2024 10:30:00 AM
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/02/2024 10:30:00 AM
- KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas • Business Wire • 03/18/2024 10:30:00 AM
- KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat • Business Wire • 03/12/2024 10:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 08:37:55 PM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM